Literature DB >> 28947935

Bruton's Tyrosine Kinase Inhibitors for the Treatment of Autoimmune Diseases and Cancers.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2017        PMID： 28947935      PMCID： PMC5601371          DOI： 10.1021/acsmedchemlett.7b00331

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

Review 1.  Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma.

Authors:  Annalisa Chiappella; Elisa Santambrogio; Alessia Castellino; Maura Nicolosi; Umberto Vitolo
Journal:  Expert Rev Hematol       Date:  2017-07-14       Impact factor: 2.929

Review 2.  Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.

Authors:  T Seiler; M Dreyling
Journal:  Expert Opin Investig Drugs       Date:  2017-07-10       Impact factor: 6.206

Review 3.  Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.

Authors:  J Molina-Cerrillo; T Alonso-Gordoa; P Gajate; E Grande
Journal:  Cancer Treat Rev       Date:  2017-06-09       Impact factor: 12.111
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.